Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Valencia
Clinical trial register · Spain

Clinical Trials in Valencia, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC
5875
Studies in scope
all four open statuses
3096
Recruiting now
open to new participants
1137
Lead sponsors
across recruiting studies
Top sites
Madrid 78 Barcelona 58 Valencia 39 Seville 29 Majadahonda 22
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
University of Valencia61 AstraZeneca60 Novartis Pharmaceuticals42 Hoffmann-La Roche41 AbbVie39 Clear sponsor filter
Site location
Madrid78 Barcelona58 Valencia39 Seville29 Majadahonda22
All 68 locations
Target enrolment
to

Trials with a site in Valencia

39 of 5875 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Spain
Start
Recruiting
AbbVie
Phase 2/3
660
Majadahonda, Pamplona, Seville, Madrid, Valencia
2026-06-30
Recruiting
AbbVie
Phase 3
990
Barcelona, Córdoba, Madrid, Valencia, Zaragoza
2026-05-22
Recruiting
AbbVie
Phase 2
165
Valencia
2026-01-23
Recruiting
AbbVie
Phase 2/3
490
Santiago de Compostela, Sabadell, Barcelona, Madrid, Málaga, Valencia, Zaragoza
2025-12-10
Recruiting
AbbVie
Phase 2
100
Pamplona, Barcelona, Madrid, Valencia
2025-12-01
Recruiting
AbbVie
Phase 3
561
Córdoba, Donostia / San Sebastian, Majadahonda, Asturias, Seville, Barcelona, Madrid, Valencia
2025-11-05
Recruiting
AbbVie
Observational
2,795
Jaén, Alcorcón, Majadahonda, Parla, San Cristóbal de La Laguna, Valencia
2025-09-02
Recruiting
AbbVie
Phase 2/3
854
Barcelona, Madrid, Valencia
2025-08-03
Recruiting
AbbVie
Phase 2
180
Sabadell, Seville, Bilbao, A Coruña, Córdoba, Madrid, Valencia
2025-06-20
Recruiting
AbbVie
Phase 2
110
Badalona, Jaén, El Palmar, Pamplona, Seville, Barcelona, Madrid, Valencia
2025-05-28
Recruiting
AbbVie
Phase 2
390
Santander, Pamplona, Barcelona, Madrid, Valencia
2025-04-24
Active, closed
AbbVie
Phase 2
185
Pamplona, Madrid, Ourense, Valencia
2024-12-13
Recruiting
AbbVie
Phase 2
488
Badajoz, Barcelona, Madrid, Valencia
2024-10-07
Recruiting
AbbVie
Phase 2
590
Santiago de Compostela, Seville, Barcelona, Madrid, Pontevedra, Valencia
2024-09-04
Recruiting
AbbVie
Phase 3
675
Esplugues de Llobregat, Madrid, Valencia, Zaragoza
2024-08-19
Active, closed
AbbVie
Phase 2
108
Barcelona, Cáceres, Jaén, Madrid, Valencia
2024-07-29
Recruiting
AbbVie
Phase 3
40
Esplugues de Llobregat, Valencia
2024-07-08
Active, closed
AbbVie
Phase 3
1,400
Sabadell, Santander, Manises, Madrid, Málaga, Valencia
2024-06-27
Recruiting
AbbVie
Phase 3
200
Granada, Madrid, Valencia
2024-06-14
Active, closed
AbbVie
Phase 3
421
Badalona, Ourense, León, Madrid, Salamanca, Valencia
2024-05-19
Recruiting
AbbVie
Phase 2/3
840
Santiago de Compostela, L'Hospitalet de Llobregat, Barcelona, Madrid, Valencia
2024-04-10
Active, closed
AbbVie
Phase 3
614
Badalona, Getafe, Pozuelo de Alarcón, Granada, Madrid, Valencia, Zaragoza
2023-12-19
Active, closed
AbbVie
Phase 2
280
Barcelona, Madrid, Valencia, Zaragoza
2023-11-12
Recruiting
AbbVie
Phase 3
1,500
L'Hospitalet de Llobregat, Fuenlabrada, Barcelona, Córdoba, Madrid, Valencia
2023-10-11
Recruiting
AbbVie
Phase 3
90
Esplugues de Llobregat, Valencia
2023-10-02
Active, closed
AbbVie
Phase 3
1,328
L'Hospitalet de Llobregat, Majadahonda, Manises, Barcelona, Granada, Madrid, Valencia
2023-06-21
By invitation
AbbVie
Phase 3
650
Barcelona, Madrid, Seville, Valencia
2023-06-05
Recruiting
AbbVie
Phase 3
450
Barcelona, Madrid, Seville, Valencia
2023-05-01
Active, closed
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
NCT05527184Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
DrugIMGN151
AbbVie
Phase 1
256
Badalona, Córdoba, Barcelona, Madrid, Valencia
2023-01-11
Active, closed
AbbVie
Phase 1
288
Barcelona, Madrid, Seville, Valencia
2022-12-05
Recruiting
AbbVie
Phase 3
768
Las Palmas de Gran Canaria, Alcorcón, Fuenlabrada, Ávila, Barcelona, Jaén, Madrid, Valencia
2022-03-25
Active, closed
AbbVie
Phase 3
531
Badalona, Córdoba, Pozuelo de Alarcón, Barcelona, Madrid, Salamanca, Seville, Valencia
2020-09-10
Active, closed
AbbVie
Phase 1/2
218
Madrid, Valencia
2019-11-06
Active, closed
AbbVie
Phase 1
124
Esplugues de Llobregat, Madrid, Valencia
2019-06-24
Active, closed
AbbVie
Phase 3
964
Badalona, Sabadell, A Coruña, Almería, Barcelona, Madrid, Valencia
2019-03-25
Active, closed
AbbVie
Phase 1
364
Pamplona, Barcelona, Madrid, Valencia
2019-02-21
Active, closed
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
NCT03386513Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm
DrugIMGN632
AbbVie
Phase 1/2
179
Valencia
2018-01-02
Active, closed
AbbVie
Phase 1
163
Majadahonda, Madrid, Valencia
2017-02-22
Active, closed
AbbVie
Phase 3
443
Pamplona, Barcelona, Madrid, Málaga, Valencia
2017-02-02
Rows per page Showing 1–39 of 39
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-spain/city/valencia

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 39 of those studies with a site in Valencia that also match the filters currently applied.

How many clinical trials are recruiting in Valencia?

21 of the 39 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 17 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Valencia), 39 studies
PhaseStudiesRecruitingShare
Phase 317943.6%
Phase 210725.6%
Phase 15012.8%
Phase 2/34410.3%
Phase 1/2205.1%
Observational112.6%

Most active sponsors

Lead sponsors with the most studies (Valencia)
Lead sponsorStudiesRecruiting
AbbVie3921
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.